NLS Pharmaceutics Ltd. – Schedule 13D filing (NLSPW)
Chairman Ronald Hafner has filed a Schedule 13D disclosing beneficial ownership of 557,131 common shares, equal to 13.2 % of the company’s 4,097,641 outstanding shares. Mr. Hafner possesses sole voting and dispositive power over the entire position; no shares are held jointly.
Capital deployment was entirely from personal funds. The filing details multiple transactions that built the position:
- Equity Purchase Agreement (10-Oct-2024): acquired 100,807 common shares plus 100,807 five-year warrants (exercise $4.25) at a combined price of $3.97.
- Warrant Amendment (9-Oct-2024): received pre-funded warrants for 1,925 shares, exercisable at CHF 0.80.
- Debt Purchase Agreement (10-Oct-2024): obtained 173,173 convertible preferred shares (conversion price $4.96) as part of a $4 m debt restructuring.
- Put-Call Agreement (Feb-2025): option exercised leading to purchase of 37,783 preferred shares for $150,000.
- Debt settlements: 111,637 common shares transferred from CEO Alexander Zwyer (7-Feb-2025) and 17,782 shares transferred from Magnetic Rock Investment AG (21-Feb-2025).
Intent: The shares are held for investment; no activist agenda is disclosed. The agreements grant limited participation rights (up to 50 % of future offerings for one year) but do not impose voting covenants. No criminal or civil proceedings are reported against the filer.
For investors, the filing signals material insider confidence and establishes Mr. Hafner as the company’s largest known shareholder, potentially aligning board decisions with shareholder value creation. No immediate dilution or earnings impact is indicated, but future conversions of preferred shares and warrant exercises could expand the float.